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Abstract
Vaccination with live attenuated classical swine fever virus (CSFV) vaccines induces a rapid onset of protection which has
been associated with virus-specific CD8 T cell IFN-c responses. In this study, we assessed the specificity of this response, by
screening a peptide library spanning the CSFV C-strain vaccine polyprotein to identify and characterise CD8 T cell epitopes.
Synthetic peptides were pooled to represent each of the 12 CSFV proteins and used to stimulate PBMC from four pigs
rendered immune to CSFV by C-strain vaccination and subsequently challenged with the virulent Brescia strain. Significant
IFN-c expression by CD8 T cells, assessed by flow cytometry, was induced by peptide pools representing the core, E2, NS2,
NS3 and NS5A proteins. Dissection of these antigenic peptide pools indicated that, in each instance, a single discrete
antigenic peptide or pair of overlapping peptides was responsible for the IFN-c induction. Screening and titration of
antigenic peptides or truncated derivatives identified the following antigenic regions: core241–255 PESRKKLEKALLAWA and
NS31902–1912 VEYSFIFLDEY, or minimal length antigenic peptides: E2996–1003 YEPRDSYF, NS21223–1230 STVTGIFL and NS5A3070–
3078 RVDNALLKF. The epitopes are highly conserved across CSFV strains and variable sequence divergence was observed
with related pestiviruses. Characterisation of epitope-specific CD8 T cells revealed evidence of cytotoxicity, as determined
by CD107a mobilisation, and a significant proportion expressed TNF-a in addition to IFN-c. Finally, the variability in the
antigen-specificity of these immunodominant CD8 T cell responses was confirmed to be associated with expression of
distinct MHC class I haplotypes. Moreover, recognition of NS21223–1230 STVTGIFL and NS31902–1912 VEYSFIFLDEY by a larger
group of C-strain vaccinated animals showed that these peptides could be restricted by additional haplotypes. Thus the
antigenic regions and epitopes identified represent attractive targets for evaluation of their vaccine potential against CSFV.
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Introduction
Classical swine fever (CSF) is a severe and often lethal viral
disease of domestic pigs and wild boars. The aetiological agent is
classical swine fever virus (CSFV), a small, enveloped, positive-
sense, single-stranded RNA virus belonging to the pestivirus genus
of the Flaviviridae family [1,2]. The disease is endemic in South East
Asia, parts of Central and South America and the Russian
Federation. Despite the stringent controls adopted in the EU, the
virus continues to be an epizootic threat with recent outbreaks in
Lithuania (2009 and 2011) and Latvia (2012) [3]. CSF is amenable
to control by vaccination and live attenuated C-strain vaccines are
highly efficacious. However, the inability to differentiate vaccinat-
ed animals from those infected with CSFV limits their utility as a
control tool in outbreak settings in the EU [4]. Control of CSF
outbreaks via a stamping-out policy is expensive, because large
numbers of animals have to be culled including those slaughtered
pre-emptively. Public resistance against such drastic measures is
also growing. As a consequence, there is increased pressure to
develop and adopt alternative strategies, like marker vaccines, to
aid the control of CSF outbreaks [4].
C-strain vaccine induced IFN-c responses have been correlated
to rapid protection against the disease [5] and CSFV-specific IFN-
c secreting CD8 T cells are detected in the blood early after
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vaccination [6]. Determining the viral proteins that are the targets
of the CD8 T cell response in immune animals would provide an
important step towards developing a next generation marker
vaccine capable of providing rapid protection against CSFV.
CSFV has four structural proteins (the core protein and the
envelope glycoproteins Erns, E1 and E2) and eight non-structural
proteins (Npro, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B)
[1]. E2 and NS3 have been described as targets of the T cell
response and both proteins induce IFN-c release [6–9] and
cytotoxic activity by T cells from vaccinated pigs [7–10]. A T cell
epitope was identified on NS4 [9] and our group recently reported
NS5B as a putative target of IFN-c secreting T cells from C-strain
vaccinated pigs [6]. Epitopes may be located on other viral
proteins, since peptides pooled to represent Erns, E1, NS2, NS4B
and NS5A were able to induce PBMC proliferation in vaccinated
pigs, but their ability to elicit an IFN-c or cytotoxic response was
not tested [9]. Most of these studies utilised inbred homozygous
pigs so were focussed on a single haplotype [7,9,10] and the
phenotype of the responding T cells/MHC restriction was not or
only partially characterized [6–10].
Knowledge of epitopes within viral proteins that are targeted by
CD8 T cell is also necessary to ensure that genetically attenuated
or sub-unit DIVA vaccines include these regions. As the major
target of neutralizing antibody responses, the structural protein E2
has been used to create subunit or chimeric vaccines [11,12].
Additional evidence that this protein is also able to target the
cellular immune response comes from a recent study which
showed that a DNA vaccine expressing E2 induced a cellular
immune response, characterized by IFN-c releasing T cells, before
the appearance of neutralizing antibodies [11]. Moreover, a
chimeric vaccine CP7_E2alf, where the E2 protein of the CSFV
strain Alfort 187 is inserted in the backbone of the bovine viral
diarrhoea virus (BVDV) strain CP7, can fully protect pigs from
challenge before the appearance of neutralizing antibodies [12].
However, it remains to be determined whether CSFV E2 specific
or BVDV cross-reactive antigen specific T cells are involved in
mediating this protection.
The ability of subunit vaccines to trigger T cell responses that
contribute to protection has been observed in other viruses
belonging to the family Flaviviridae, such as hepatitis C virus (HCV)
[13-15] and dengue virus (DENV) [16,17]. Both a HCV peptide-
vaccine, including 5 MHC-class I and 3 MHC class-II-restricted
epitopes, a DNA vaccine encoding NS3 and NS4 and an
adenovirus-based vaccine expressing NS3 of HCV induce a strong
CD8 T cell response in vaccinated individuals [13–15]. DNA
vaccines based on the NS3 protein from DENV and an adenovirus
expressing DENV NS1 induce a peptide-specific IFN-c response
by CD8 T cells from vaccinated mice which correlated with
protection [16,17].
With a view to better defining the protein and epitope targets of
the CD8 T cell response in pigs protected against CSF by
vaccination with a live-attenuated C-strain vaccine; we screened a
peptide library spanning the CSFV proteome. Five T cell antigens
and the corresponding antigenic regions/epitopes were identified.
The conservation of these peptides across CSFV strains was
assessed as were the restricting MHC class I haplotypes and the
CSFV-specific T cells responding were phenotypically and
functionally characterized.
Materials and Methods
Ethics Statement
All work was approved by the Animal Health and Veterinary
Laboratories Agency Ethics Committee and all procedures were
conducted in accordance with the UK Animals (Scientific
Procedures) Act 1986 under project licence permit numbers PPL
70/7403 and PPL 70/6559. Regular observation and completion
of clinic scoring sheets was conducted, which informed euthanasia
decisions based on a pre-defined humane endpoint (clinical score
.15 or if temperature .41uC and more than 2 individual scores
(other than the temperature score) have a value of 3) and
minimised potential suffering to the animals. None of the animals
reported in this study experienced clinical signs necessitating
euthanasia. All animals were euthanized on pre-determined days
by intramuscular administration of Ketamine/Rompun sedative
followed by intravenous administration of 20% sodium pentobar-
bitone solution.
Viruses
A commercial live attenuated C-strain CSFV (genotype 1.1, AC
RiemserH Schweinepestvakzine, Riemser Arzneimittel AG, Riems,
Germany), the highly virulent Alfort-187 (genotype 1.1, AHVLA
CSF Reference Laboratory Virus Archive, Addlestone, UK) and
Brescia (genotype 1.1, kindly provided by Dr Alexandra Meindl-
Bo¨hmer, University of Veterinary Medicine, Hannover, Germany)
strains, the moderately virulent UK2000/7.1 (a genotype 2.1
isolate from the UK [18]) and CBR/93 (a genotype 3.3 isolate
kindly provided by Dr Sujira Parchariyanon [19]) strains of CSFV
were propagated in porcine kidney (PK15) cells maintained in
Eagle’s Minimum Essential Medium (E-MEM) (Life Technologies,
Paisley, UK) with 10% FBS (Autogen Bioclear, Calne, UK) and
antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin, both
from Life Technologies). CSFV was harvested from cultures after
4 days and TCID50 titres were determined according to standard
protocols [20]. Mock virus supernatants were prepared in an
identical manner from uninfected PK15 cells.
Vaccination and challenge of pigs with CSFV
Experiment 1. An experimental vaccination/challenge study
was performed to assess the specificity of CSFV-specific CD8 T
cell IFN-c responses, as previously described [21]. In brief, eleven
Large White/Landrace pigs, 6 months of age, were utilized; eight
animals were vaccinated 5 days before challenge (day -5) by
intramuscular inoculation of 105 TCID50 of C-strain CSFV and
challenged on day 0 and 28 by intranasal inoculation of 105 and
106 TCID50 of CSFV Brescia, respectively (1 ml divided equally
between each nostril and administered using a mucosal atomiza-
tion device MAD-300, Wolfe Tory Medical, Salt Lake City, USA).
Three negative control pigs received similar inoculations of mock
virus supernatant on each occasion. Virus back titrations of the
inocula confirmed the vaccine and challenge doses were those
expected.
Experiment 2. A second vaccination/challenge study assess-
ed recognition of identified T cell epitopes by additional C-strain
vaccinated pigs. Animals vaccinated and challenged in two
independent, previously described, experiments [5] were utilised.
Large White/Landrace cross male pigs, 9 weeks of age, were
vaccinated intramuscularly with 2 ml of reconstituted C-strain
vaccine, as described by the manufacturer (Riemser Arzneimittel
AG) and after 3 or 5 days were challenged by intranasal
inoculation of 105 TCID50 CSFV UK2000/7.1 or CBR/93
strains as described above.
Clinical and haematological methods
Temperatures and clinical scoring were monitored for 7 days
before and after each of the CSFV Brescia inoculations for
Experiment 1 [21] and from day -5 to 15 days post-challenge for
Experiment 2 [5]. Nine parameters relevant for indication of CSF
Specificity of the CD8 T Cell Response to CSFV
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(liveliness, body tension, body shape, breathing, walking, skin, eye/
conjunctiva, appetite/leftover at feedings, defecation) were exam-
ined and scored as 0 (normal), 1 (slightly altered), 2 (distinct clinical
sign) or 3 (CSF signs). A total clinical score for each animal was
assigned twice daily and temperatures were monitored by daily
rectal thermometer readings [22]. Peripheral blood leukocyte
counts were monitored by volumetric flow cytometry during both
experiments [22]. In brief, 50 ml EDTA blood was incubated with
5 ml of anti-porcine CD45-FITC monoclonal antibody (mAb)
(0.1 mg/ml, K252-1E4, AbD Serotec, Oxford, UK) for 10
minutes at room temperature (RT) in the dark. FACS Lysing
solution (945 ml) (BD Biosciences, Oxford, UK) was added for 10
minutes at RT to lyse erythrocytes and fix leukocytes. Cell counts
were obtained on a volumetric flow cytometer (MACSQuant
Analyzer, Miltenyi Biotec, Bisley, UK) by gating FITC positive
events and leukocyte counts per ml/blood were obtained by
multiplying the leukocyte density by the dilution factor (x 20).
Purification and cryopreservation of peripheral blood
mononuclear cells (PBMC)
Heparinised venous blood was collected on days -5, 0 and every
7 days until day 56 post-challenge for Experiment 1 and every
three days from day -5 to 15 post-challenge for Experiment 2.
PBMC were prepared by diluting 20 ml of blood in 10 ml PBS
(Life Technologies), layering over 20 ml of Histopaque-1077
(Sigma-Aldrich, Poole, UK) and centrifuging at 14556g for 30
minutes at room temperature (RT), without braking, in a rotating
bucket centrifuge. PBMC were aspirated from the plasma-
Histopaque-1077 interface and washed three times in PBS by
centrifugation at 9306g for 5 minutes at 4uC. PBMC were re-
suspended in RPMI-1640 medium (Life Technologies) supple-
mented with 10% FBS, 100 U/ml penicillin and 100 mg/ml
streptomycin (cRPMI) and cell densities determined using a
volumetric flow cytometer (Miltenyi Biotec) and gating on events
with typical forward scatter (FSC) and side scatter (SSC) for
PBMC. Cells were used directly for phenotypic/functional analysis
or cryopreserved for subsequent analysis.
For cryopreservation, PBMC were adjusted to a density 1–
26107 cells/ml, re-suspended in cold (4uC) 10% DMSO (Sigma-
Aldrich) in FBS and transferred to pre-cooled (4uC) labeled
cryotubes. These tubes were immediately transferred to pre-cooled
(4uC) Cryo 1uC Freezing Container (Nalgene, Fisher Scientific,
Loughborough, UK) pre-filled with 250 ml of 100% isopropyl
alcohol, which was placed in a 280uC freezer for a minimum of
4 hours to a maximum of 24 hours. Cryotubes were then
transferred to a liquid nitrogen storage container.
Synthetic CSFV peptides
A synthetic overlapping peptide library was designed which
comprised pentadecamer peptides off-set by four residues. The
peptide sequences were designed using the predicted polyprotein
of CSFV C-strain Riems (GenBank accession number
AY259122.1). The synthesized library of 945 peptides (JPT
Peptide Technologies, Berlin, Germany) was reconstituted in
sterile 10 mM HEPES (Life Technologies) buffered 40% acetoni-
trile (Sigma-Aldrich) at a concentration of 1 mg/ml. For initial
screening, peptides were combined into pools representing the
structural and non-structural proteins of CSFV and diluted in
cRPMI and used at a final total peptide concentration of 1 mg/ml,
unless otherwise stated. In order to identify the antigenic peptides
from positive pools, a two-way matrix system was adopted to
screen peptides representing the non-structural proteins: NS5A,
NS3, NS2 and the structural protein E2. Matrix pools were
designed so that each peptide was uniquely present in 2 different
pools. The 121 NS5A peptides were prepared in 22 peptide pools
(A-V), the 110 NS2 peptides in 21 peptide pools (A-U), the 168
NS3 peptides 26 peptide pools (A-Z) and the 90 E2 peptides in 19
matrix peptide pools (A-S). An illustration of how the peptides
were combined into matrix pools is shown in Table 1 using NS2
peptides as an example. After identification of the antigenic
pentadecamers, truncated 8-11mers of consensus antigenic
sequences were designed, synthesised (JPT Peptide Technologies),
reconstituted and prepared as described above.
Porcine IFN-c ELISpot assay
ELISpot plates (96 well Multiscreen-IP Filter Plates; Millipore,
Watford, UK) were prepared by pre-wetting each well with 15 ml
of 35% ethanol for 1 min then washing 3 times with sterile PBS.
The capture antibody (anti-porcine IFN-c mAb, P2G10, BD
Biosciences, Oxford, UK), prepared at 0.5 mg/ml in PBS, was
added at 50 ml/well and the plates incubated at 4uC overnight.
Capture antibody was then decanted and plates washed 3 times
with unsupplemented RPMI-1640 medium. Plates were blocked
by addition of 100 ml/well cRPMI and incubation for at least 1 hr
at 37uC. Freshly isolated PBMC were suspended at 56106/ml in
cRPMI and 100 ml of cells was added to each well. CSFV Alfort
187 strain was diluted in cRPMI and added at a multiplicity of
infection (MOI) of 1. Concanavalin A (Sigma-Aldrich) at 10 mg/
ml and mock virus-infected PK-15 cell cryolysate supernatant
were used as positive and negative controls, respectively. All
conditions were tested in triplicate and plates were incubated at
37uC in a 5% CO2 humidified atmosphere for 18 hours. Well
contents were discarded and 100 ml of cold water was added to
each well and incubated for 5 min. Wells were then washed 5
times with PBS containing 0.05% Tween 20 (ELISpot Wash
Buffer). Biotinylated anti-porcine IFN-c mAb (P2C11, BD
Biosciences, Oxford, UK), diluted to 0.167 mg/ml in PBS,
0.05% Tween 20, 1% FBS was added (50 ml/well) and plates
incubated at 4uC overnight. Plates were washed 3 times with
ELISpot Wash Buffer and incubated with streptavidin-HRP (R&D
Systems, Abingdon, UK; 0.5 mg/ml, 50 ml/well) for 1 hr at 37uC.
After plates were washed 5 times, BCIP/NBT substrate (R&D
Systems, Abingdon, UK, 100 ml/well) was added and plates
incubated at RT in the dark until spots became visible, typically
15–60 min. The substrate was then discarded and the plates
washed extensively with water and left to dry in the dark. Spots
were visualized using an automated ELISpot reader (AutoImmun
Diagnostika, Strabberg, Germany).
Multi-parameter cytofluorometric analysis of PBMC
responses
Both freshly isolated and cryopreserved PBMC were used in this
study. To resuscitate cryopreserved cells, cryovials were rapidly
thawed in a 37uC water bath and cells transferred to tubes
containing 10 ml of pre-warmed (37uC) cRPMI. Cells were
washed by centrifugation, 9306g for 5 minutes at RT, and
resuspended in fresh warm cRPMI. Cell densities were calculated
using flow cytometry as described above and adjusted to
16106 cells/ml and 100 ml transferred to wells of a 96-well round
bottom microtitre plate (Costar, Fisher Scientific). PBMC were
stimulated with 100 ml of CSFV Alfort-187 strain, at a MOI= 1,
or with 100 ml of peptide pools or individual peptides at 1 mg/ml,
unless otherwise stated. Mock-virus PK15 supernatants/cRPMI
medium and ConA (10 mg/ml) were used as negative and positive
controls, respectively. Cells were incubated at 37uC for 2 (peptide-
stimulation) or 14–16 (virus-stimulation) hours and then brefeldin
A (GolgiPlug, BD Biosciences) was added (0.2 ml/well) and cells
were further incubated for a further 16–18 or 6 hours following
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stimulation with peptide or CSFV, respectively. To detect
cytotoxic degranulation, CD107a-Alexa Fluor 647 or IgG1 isotype
control-Alexa Fluor 647 mAbs (both AbD Serotec, Oxford, UK;
10 ml/well) and monensin (Golgi Stop, BD Biosciences; 0.2 ml/
well) were added in conjunction with Brefeldin A.
Cells were washed in Dulbecco’s PBS without Mg2+ and Ca2+
(DPBS; Life Technologies) and stained with Near Infra-Red
Fixable Live/Dead Viability Dye (Life Technologies) for 30
minutes at 4uC. Cells were washed twice with DPBS supplemented
with 2% FBS and 0.09% sodium azide (FACS buffer) and stained
with mAbs specific for surface markers for 10 min at RT: CD8a-
PE (76-2-11, BD Biosciences) and CD4-PerCP-Cy5.5 (74-12-4,
BD Biosciences), CD25 (K231.3B2, AbD Serotec) and CD27
(b30c7, kindly provided by Dr Wilhelm Gerner, University of
Veterinary Medicine, Vienna, Austria [23]). Cells were washed
twice with FACS buffer and staining with CD25 and CD27 was
visualized by incubation of cells with APC-conjugated rat anti-
mouse IgG1 (BD Biosciences) for 10 min at RT and then washed
twice with FACS buffer. Surface stained cells were fixed and
permeabilised using CytoFix/CytoPerm Solution (BD Bioscience)
for 20 min at 4uC. After two washes in BD Perm/Wash Buffer
(BD Biosciences), PBMC were incubated with cytokine specific
mAbs at RT for 10 minutes in the dark. mAbs used for cytokine
staining were: IFN-c-FITC or –Alexa Fluor 647 (CC302, AbD
Serotec), TNF-a-Pacific Blue (MAb11, Biolegend, Cambridge
BioScience, Cambridge, UK) and IL-2 (A150D 3F1, Life
Technologies), labelled using Zenon Alexa Fluor 647 mouse
IgG2a labelling kit (Life Technologies). IgG1-FITC or –Alexa
Fluor 647 isotype control mAbs were used to control staining with
IFN-c mAbs. Un-stained cells were used as control for IL-2 and
TNF-a. The cells were given two final washes in BD Perm/Wash
buffer and re-suspended in FACS buffer prior to flow cytometric
analysis on a MACSQuant Analyzer (Miltenyi Biotec) or CyAn
ADP (Beckman Coulter, High Wycombe, UK) flow cytometers.
Cells were analyzed by exclusion of doublets, followed by gating
on viable cells (Live/Dead Fixable Dead Cell Stain negative) in the
lymphocyte population and defined lymphocyte subpopulations
were then gated upon and their expression of cytokines assessed.
Gates were set using the corresponding isotype/unstained controls
and values were corrected by subtraction of the % positive events
in the biological negative control (cRPMI or mock-virus superna-
tant stimulated). The number of singlet live lymphocytes acquired
for analysis ranged from 200,000–400,000, which translated to
20,000–80,000 CD8 T cells being analysed.
Sequence analysis of T cell antigenic peptides/epitopes
The sequences of the identified T cell antigenic regions/
epitopes were aligned against the predicted full-length polyprotein
sequences of 14 CSFV isolates (GenBank accession numbers
shown in parentheses): Genotype 1.1 - Brescia (AF091661), Alfort/
187 (X87939.1), KC Vaccine (AF099102), ALD (D49532), GPE2
(D49533), Alfort-A19 (U90951), cF114 (AF333000), Shimen
(AF092448), Koslov (HM237795) and SWH (DQ127910); Geno-
type 2.1 - Penevezys (HQ148063); Genotype 2.3 - Borken
(GU233731) and Alfort Tu¨bingen (AAA43844); Genotype 3.4 -
94.4/IL/94/TWN (AY646427.1); the BVDV reference strain
NADL (AJ133738) and the border disease virus (BDV) reference
strain BD31 (U70263), using the clustal W algorithm on MegAlign
(DNAStar Lasergene 9 Core Suite, Madison, WI, USA).
The sequences of the identified T cell antigenic regions/
epitopes were also aligned with the corresponding sequences of the
CSFV isolates UK2000/7.1 [18] and CBR/93 [19]. These
sequences were generated using RNA from CSFV strains
UK2000/7.1 and CBR/93 and creating cDNA by reverse
transcription as previously described [22]. A 5 ml aliquot of cDNA
was used as template for PCR amplification with high fidelity
Platinum Taq in a 45 ml reaction mix containing: 1 ml dNTP
(10 mM of each dNTP, Promega, Southampton, UK), 5 ml 10x
PCR buffer, 1.5 ml MgSO4 (50 mM), 0.2 ml Platinum Taq (5 U/
ml) (all Life Technologies) and 0.5 ml of each 20 mM primer
solution (Sigma-Aldrich). The following primers (59-39) were used
to amplify the region encoding the viral proteins Npro, Core and
Erns: HE5 TGGGAGTGGAGGAACCG and HE ErnsR
TCNGGGGCGAAGTCAGACA. Sequencing was achieved with
these primers together with HE2 GTGATGGGRGTACGA
CCTGATAGG, Core-F-954 AGAGCATGAGAAGGACAGYA,
Core-R-1211 GTGCCRTTGTCACTYAGGTT, HE15 ErnsR
internal GTGTACCATATATACCCTATT, HE16 ErnsR inter-
nal GTCTATGTTGTACCAGTTGC and HE ErnsF CAA-
GAYGGCCTGTACCAYAAY. The other viral coding regions
Table 1. Example of the two-way matrix-pooling system used to identify T cell reactive peptides from pools representing CSFV
proteins.
NS2 Matrix pools*
A B# C D E F G H I# J K
NS2 Matrix pools contd. L 1 2 3 4 5 6 7 8 9 10 11
M 12 13 14 15 16 17 18 19 20 21 22
N 23 24 25 26 27 28 29 30 31 32 33
O# 34 35 36 37 38 39 40 41 42 43 44
P# 45 46 47 48 49 50 51 52 53 54 55
Q 56 57 58 59 60 61 62 63 64 65 66
R 67 68 69 70 71 72 73 74 75 76 77
S 78 79 80 81 82 83 84 85 86 87 88
T 89 90 91 92 93 94 95 96 97 98 99
U 100 101 102 103 104 105 106 107 108 109 110
*The 110 overlapping 15mer peptides (#1-110) representing CSFV NS2 were pooled using a matrix system so that each peptide was uniquely represented in two
matrix-pools (Pools A-U).
#Matrix pools B, I, O and P stimulated CD8 T cell reactivity from Pig AN7 and so NS2 peptides #35, 42, 46 and 53 were identified for further testing.
doi:10.1371/journal.pone.0084246.t001
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were amplified and sequenced with the same primer pairs,
specifically primers used for E2 were E2-F-2846 GTCRTA-
GAGTGCACRGCAGT and E2-R-3613 GTGTGGGTRAT-
TAAGTTCCCTA, for NS2 were NS2-F-3840 TAGTAGTC-
GYYGTGATGTTR and NS2-R-4248 GCCCACATCGTA-
AAMACCA, for NS3 were NS3-F-5974 AGGATAGGKGA-
GATGAAGG and NS3-R-6332 TTCATCTCCTCTACTGG-
TATC and for NS5A were NS5A-F-9278 ACTATGACTA-
CAGGGGAG and NS5A-R-9857 GATATCTTTGTGGAGT-
CTGT. The following thermal profile was adopted: 94uC for 2
minutes, 406 (94uC 30 seconds; 53uC 30 seconds for E2/49uC 30
seconds for core and NS3/46uC 30 seconds for NS2 and NS5A;
72uC 60 seconds); 72uC 1 minute and a 4uC hold. Sequencing
reactions using purified amplicons were set up in both directions
using standard Sanger sequencing (Central Sequencing Unit,
AHVLA, Addlestone, UK) the amino acid sequences deduced
from the assembled amplicon sequences were aligned with the
matching antigenic peptide.
MHC class I haplotype determination by low-resolution
(Lr) PCR-based analysis
Pigs used in this study were genotyped for their swine leukocyte
antigen (SLA) class I haplotypes by low-resolution PCR screening
assays (PCR-SSP) on PBMC-derived genomic DNA as previously
described [24].
Data analysis and statistics
Graphical and statistical analysis was performed using Graph-
Pad Prism 5.04 (GraphPad Software Inc, La Jolla, USA). Data was
represented as means with standard error of means (SEM) quoted
to indicate the uncertainty around the estimate of the group mean.
A two-tailed unpaired t-test or a one-way-analysis-of-variance
(ANOVA) followed by a Dunnett’s multiple comparison test was
used and a p-value ,0.05 was considered statistically significant.
Nucleotide and predicted amino acid sequence GenBank
accession numbers
The nucleotide and predicted amino acid sequences from CSFV
UK2000/7.1 and CBR/93 which include the identified antigenic
peptides/epitopes have been deposited in GenBank under the
following accession numbers: CSFV UK2000/7.1 NS2
(KF771869), NS3 (KF771871) and NS5A (KF771873) and CSFV
CBR/93 core (KF784898), E2 (KF771867), NS2 (KF771868),
NS3 (KF771870) and NS5A (KF771872). The following existing
submissions displayed 100% identity with sequenced regions for
CSFV UK2000/7.1 core (AFJ79223) and E2 (JQ411582),
Results
Detection of CSFV-specific CD8 T cell responses following
vaccination and challenge
Animals vaccinated in Experiment 1 were solidly protected
against both challenge infections, at 5 and a further 28 days post
vaccination, with no evidence of leukopenia or clinical signs of the
disease being observed (data not shown [21]). One week after the
second challenge inoculation a significant IFN-c response follow-
ing in vitro stimulation with CSFV was observed in PBMC from
vaccinated/challenged (V/C) animals, but not control pigs
(Fig. 1A). Using the flow cytometric gating strategy displayed in
Fig. 1B, CSFV-specific IFN-c expression was detected in the
CD42CD8ahigh and CD4+CD8alow populations, which in swine
have been proposed to represent CD8 and activated/memory
CD4 T cell populations respectively [25]. CSFV-specific IFN-c
responses were detected in PBMC from V/C animals, but not
control pigs, with the CD8 T cell population dominating the IFN-
c response (Fig. 1C). From the 8 V/C pigs, the greatest CD8 T cell
response was identified in pigs AN5, AN7, AN11 and AN13, and
these animals were selected for an in-depth analysis of the
specificity of their CD8 T cell responses.
Screening of a CSFV proteome-wide peptide library to
identify CD8 T cell antigens
To identify CSFV T cell antigens, PBMC from the four selected
V/C pigs were stimulated in vitro with pools of overlapping 15mer
peptides representing the 12 CSFV proteins and CD8 T cell
reactivity was screened using IFN-c detection by flow cytometry
(Fig. 2). Significant IFN-c responses were observed in all V/C
animals and each animal reacted against a unique profile of
antigens. Pig AN5 mounted a significant IFN-c response against
NS3 and NS5A peptides, pig AN7 reacted significantly against the
NS2 peptide pool, pig AN11 responded to peptides representing
the E2 and NS3 proteins and pig AN13 mounted the greatest
response to the core peptides with significant reactivity also
observed against NS5A.
Identification of CD8 T cell epitopes on CSFV
To identify the peptide targets of these CD8 T cell IFN-c
responses, a two way matrix system was adopted to screen peptides
representing the non-structural proteins NS5A, NS3, NS2 and the
structural protein E2, whereas the peptides spanning the core
protein were screened individually. The matrix pools were
designed so that each peptide was uniquely present in 2 defined
pools. An illustration of how peptides were combined into matrix
pools and how the CD8 T cell IFN-c responses to these pools
enabled the identification of putative antigenic peptides is shown
in Table 1, using NS2 peptides as an example. PBMC from pigs
AN5 and AN13 were stimulated in vitro with the NS5A matrix
peptide pools and IFN-c+ CD8 T cells were identified using flow
cytometry. Pools C, K, N and Q induced a significant IFN-c
response in CD8 T cells from pig AN5 (Fig. 3). By analysing the
peptide constituents of the reacting matrix pools, four potential
antigenic 15mers were identified for further testing: peptides #25,
33, 58 and 66. Pig AN13 did not mount a significant CD8 T cell
IFN-c response to any of the NS5A matrix pools. PBMC from pig
AN7 were stimulated with the NS2 matrix peptide pools and a
CD8 T cell IFN-c response was observed against pools B, I, O, P
(Fig. 3) identifying 4 putative antigenic peptides: #35 42, 46 and
53. PBMC from pigs AN5 and AN11 were stimulated in vitro with
Figure 1. Vaccination with C-strain and challenge with virulent CSFV induces predominately a virus-specific IFN-c CD8 T cell
response. Pigs were vaccinated on day -5 and then challenged with CSFV Brescia strain on days 0 and 28 post-challenge. Seven days after the
second challenge, PBMC from vaccinated/challenged (V/C) and control animals stimulated with CSFV and IFN-c release measured by ELISpot assay.
Panel A shows the mean mock-virus stimulated corrected IFN-c spot-forming cells (SFC)/56105 PBMC for each group and error bars represent SEM.
Panel B shows the gating strategy used to interrogate responses in singlet, live CD8 T cells (CD8ahighCD4-) and memory CD4 T cells (CD8alowCD4+)
[25]. Representative dot plots show the IFN-c staining of singlet, live CD8 T cells following stimulation with mock-virus or CSFV. Panel C shows the
mean mock-virus stimulated corrected % IFN-c expressing memory CD4 T cells and CD8 T cells +/2 SEM. for 8 V/C animals and 3 control animals.
Values of control and V/C groups were compared using a two-tailed un-paired t-test and significance is indicated by **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0084246.g001
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the NS3 matrix peptide pools and peptides present in the pools D,
F, G, X, Y and Z induced a statistically significant CD8 T cell
IFN-c response, which indicated that peptides #134, 136, 137,
147, 149, 150, 160, 162 and 163 were potentially antigenic. Pig
AN5 did not mount a significant response to the NS3 matrix pools.
E2 matrix peptide pools were screened with PBMC from pig
AN11 leading to the identification of significant reactivity against
pools E, G, O and P; suggesting reactivity against peptides 45, 47,
55 and 57.
The identified putative antigenic peptides were next screened
individually to assess their recognition by CD8 T cells. PBMC
from pig AN5 were found to show significant reactivity to
overlapping NS5A peptides 33 and 58, but not 25 and 66,
suggesting that a single epitope lay in the 11mer consensus region
LSRVDNALLKF (data not shown). Of the four possible antigenic
NS2 peptides, we observed that the overlapping peptides 42 and
46, with the consensus sequence LISTVTGIFLI, but not 35 and
53, induced a statistically significant greater number of IFN-c
expressing CD8 T cells from pig AN7 compared to un-stimulated
controls (data not shown). PBMC from pig AN11 showed
significant reactivity against two pairs of overlapping peptides,
E2 peptides 47 and 55 and NS3 peptides 134 and 163 with 11mer
consensus sequences of RYYEPRDSYFQ and VEYSFIFLDEY,
respectively (data not shown). Due to its short length, peptides
spanning the core protein were screened individually using PBMC
from pig AN13. Significant CD8 T cell IFN-c responses were
observed against the 15mer peptide #20 (PESRKKLEKAL-
LAWA) (Fig. 3).
The length of CD8 T cell epitopes can vary between 8 and 11
amino acids. In order to identify the minimal length antigenic
peptides and define the natural epitopes, we synthesised the two
possible 10mer, three 9mer and four 8mer sequences for each
consensus 11mer sequence of overlapping peptide pairs (NS5A-
LSRVDNALLKF NS2-LISTVTGIFLI, E2-RYYEPRDSYFQ).
Due to a limitation in the numbers of PBMC cryopreserved from
pigs AN13 and AN11, we were unable to identify the minimal
length antigenic peptides for NS31902–1912 VEYSFIFLDEY (pig
AN11) and core241–255 PESRKKLEKALLAWA (pig AN13)
regions. Following stimulation of PBMC from pig AN5 with the
NS5A 11mer LSRVDNALLKF and truncated derivatives
(Fig. 4A), one 10mer, two 9mers and the four 8mers induced a
statistically significant lower number of IFN-c producing CD8 T
cells than the 11mer, suggesting that the 9mer RVDNALLKF was
the minimal length antigenic peptide. Similar analysis with pig
AN7 (Fig. 4B) identified the minimal length antigenic peptide on
NS2 to be the 8mer STVTGIFL. A 8mer, YEPRDSYF, located
on E2, was identified as being the shortest peptide recognised by
CD8 T cells from pig AN11 (Fig. 4C). Responses to all antigenic
peptides were all shown to be dose-dependent and the threshold
concentration at which responses became undetectable was
proportional to the frequency of the peptide specific T cell
population (Fig. 4D–H).
The sequences of CD8 T cell epitopes are well conserved
among CSFV strains
Using the Clustal W protein alignment tool, we investigated the
conservation of the identified CD8 T cell epitopes/antigenic
regions among different CSFV strains (Table 2). We observed that
the antigenic region PESRKKLEKALLAWA, located on core
protein, showed only one amino acid substitution in the genotype
3.3 strain CBR/93. The NS3 11mer VEYSFIFLDEY displayed
one amino acid substitution in the genotype 2.1 strains Penevezys
and UK2000/7.1. The E2 epitope YEPRDSYF was 100%
conserved across all the CSFV strains analysed. The NS2 epitope
STVTGIFL was conserved in all the CSFV strains analysed
except the Penevezys strain, where there was a single amino acid
substitution. The NS5A epitope RVDNALLKF was conserved
Figure 2. CD8 T cells from pigs vaccinated with C-strain and
challenged with virulent CSFV display distinct profiles of
antigen reactivity. Fourteen days after re-challenge with CSFV
Brescia strain, PBMC from four selected pigs were stimulated with
synthetic peptide pools representing the 12 CSFV proteins and IFN-c
expression was assessed by flow cytometry. Graphs show the mean
unstimulated corrected % IFN-c+ CD8 T cells for each animal in
response to peptide pools +/2 SEM. Statistical analyses were performed
using a one-way ANOVA followed by a Dunnett’s multiple comparison
test versus the unstimulated cells; ***p,0.001, **p,0.01.
doi:10.1371/journal.pone.0084246.g002
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Figure 3. Identification of putative antigenic peptides recognised by CSFV specific CD8 T cells. Twenty one days after re-challenge,
PBMC from pigs AN5, AN7, AN11 and AN13 were stimulated with synthetic peptides pooled in a 2-way matrix for proteins E2 (pig AN11), NS2 (pig
AN7), NS3 (pigs AN5 and AN11) and NS5A (pigs AN5 and AN13). Peptides representing the core protein were screened individually (pig AN13). IFN-c
expression by CD8 T cells was assessed by flow cytometry as described above. The mean unstimulated corrected % IFN-c expressing CD8 T cells are
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among all genotype 1.1 strains tested except Shimen, where a
single amino acid substitution was observed. This amino acid
substitution was observed in the genotype 2.1 UK2000/7.1 strain
together with a second substitution, which was present in the other
genotype 2 strains analysed, and 2–3 substitutions were found in
the two genotype 3 strains. When compared to the reference
BVDV and BDV strains, the antigenic regions/epitopes on core,
NS3 or E2 showed no or single amino acid substitutions, 2–3
substitutions were observed in the NS2 epitope and the NS5A
epitope was poorly conserved with only three amino acids being
shared (Table 2).
Differences in CD8 T response specificity is associated
with distinct MHC class I haplotype expression
We investigated whether the different specificity of CD8 T cell
responses between pigs was due to them bearing different MHC
class I haplotypes. The porcine swine leukocyte antigen (SLA) class I
(SLA-1, SLA-2 and SLA-3) haplotypes of the four pigs were
determined using a PCR-SSP-based typing assay. Each animal was
heterozygous and no two haplotypes were shared between these
animals (Table 3). To assess the recognition of the identified T cell
epitopes and antigenic peptides by a larger number of C-strain
vaccinated pigs, PBMC collected during Experiment 2 were
assayed. Pigs were vaccinated with the C-strain and challenged
after 5 or 3 days with the virulent CSFV strain UK2000/7.1 (n= 9)
or CBR/93 (n= 7). These animals were solidly protected against
challenge with no evidence of leukopenia, viraemia or clinical signs
of the disease being observed (as described previously, [5]). Four C-
strain vaccinated/UK2000/7.1 challenged pigs (AD53, AD56,
AD62 and AD65) and two C-strain vaccinated/CBR/93 chal-
lenged pigs (AE15 and AE17) reacted against the NS2 8mer
STVTGIFL, with a significantly greater number of IFN-c
expressing CD8 T cells observed compared to unstimulated cells
(Fig. 5). A significant CD8 T cell IFN-c response against the NS3
11mer VEYSFIFLDEY was detected in three C-strain vaccinated/
UK2000/7.1 challenged pigs (AD57, AD64 and AD66) and three
C-strain vaccinated/CBR/93 challenged pigs (AE4, AE8 and
AE16). No responses were observed in these animals against the
core, E2 or NS5A peptides (data not shown). To assess whether
recognition of the two antigenic peptides was associated with the
previously identified MHC class I haplotypes, all animals were
typed for SLA class I using the PCR-SSP-based assay (Table 3). No
haplotypes were found to be shared between these pigs and the
animals used to define the antigenic peptides, but all pigs that
reacted against NS2 8mer STVTGIFL displayed the haplotype Lr-
22.0 and pigs that reacted against the NS3 11mer VEYSFIFLDEY
carried the Lr-01.0 haplotype. Interestingly three NS3 reactor
animals also expressed Lr22.0 but no response was detected against
NS2. Since we had found that the NS3 11mer VEYSFIFLDEY had
a single amino acid substitution in the UK2000/7.1 sequence (a
tyrosine at position 4), we assayed responses to both the C-strain and
UK2000/7.1 NS3 11mer peptides and found they stimulated
comparable CD8 T cell IFN-c responses in SLA-I Lr-01.0 pigs
challenged with CSFV UK2000/7.1 (data not shown).
Functional and phenotypic characterization of CSFV
peptide-specific CD8 T cells
The ability of the five identified antigenic peptides to elicit
cytotoxic activity was investigated by assessment of surface
mobilisation of CD107a, a marker of degranulation, by IFN-c+
CD8 T cells. Over 90% of IFN-c+ CD8 T cells expressed CD107a
on their surface after peptide stimulation, suggesting cytotoxic
activity of these cells against the peptide-presenting cells (Fig. 6).
With the aim to further characterize the epitope-specific CD8 T
cell populations, the expression of the activation markers CD25
and CD27 on IFN-c+ CD8 T cells were investigated using flow
cytometry. Interestingly, the majority of peptide-specific IFN-c+
CD8 were CD252 and CD27+ (Fig. 6). However, differences were
observed in levels of CD27 expression between animals/antigenic
peptides with the majority of CD8 T cells that responded to NS5-
RDNALLKF expressing high levels of CD27, whereas the others
showed the largest proportion of IFN-c+ CD8 T cells in the
CD27low population (Fig. 6). We finally analysed the ability of
CD8 T cells to produce other cytokines in response to peptide
stimulation. The ability of IFN-c+ CD8 T cells to express IL-2 and
TNF-a after peptide stimulation was assessed, using the gating
strategy illustrated in Fig. 7A. While variability was observed in
responses between animals/antigenic peptides, the majority of
peptide-specific CD8 T cells expressed either IFN-c alone or IFN-
c and TNF-a (Fig. 7B). Only a small proportion expressed IFN-c
and IL-2 or all three cytokines, with the largest populations being
observed in response to the E2 and core peptides. Interestingly, the
cells co-expressing TNF-a or TNF-a/IL-2 expressed incremen-
tally greater amounts of IFN-c compared to cells which expressed
IFN-c alone or IFN-c and IL-2 (Fig. 7C), indicative of a greater
‘quality’ of cytokine response.
Discussion
Despite presenting the porcine immune system with a poly-
protein of almost 4000 amino acids in length, this study has shown
that the CD8 T cell response to CSFV is highly focussed,
dominated by only one or two epitopes each located on five
different viral antigens (core, E2, NS2, NS3 and NS5A).
Moreover, the specificity of the response varied between animals
dependent upon their MHC class I haplotype, which present a
high degree of polymorphism in pigs [26]. The antigenic
sequences identified in this study showed no overlap with those
previously mapped [9,10]. The most likely reason for this is the
MHC haplotype of the animals studied which in the case of the
two earlier studies were inbred pigs homozygous for SLA class I
haplotype 4a.0. Interestingly, low resolution SLA class I typing
suggested that pig AN5 carried haplotype 4.0 and this was
confirmed by allele specific PCR (data not shown). It therefore
seems likely that the immunodominant response to NS5A was
restricted by one of the SLA-1 Lr-24.0 alleles at the expense of
responses directed against peptides restricted by the SLA-1 4a.0
alleles. While the underlying mechanisms are unclear, there is
evidence that the focussing of CD8 T cell responses toward
dominant epitopes can lead to a form of immune suppression of T
cells with differing specificities, a process referred to as
‘‘immunodomination’’ [27]. Immunodomination may also explain
that, while responses to NS21223–1230 and NS31902–1912 peptides
appeared restricted by the Lr-22.0 and 01.0 haplotypes, respec-
tively, animals that were heterozygous for these haplotypes
mounted responses solely against NS3. Two of the peptides
identified in this study, NS31902–1912 and E2996–1003, were
homologous to antigenic regions we previously identified using
BVDV peptides to screen CSFV-specific T cell responses [6].
presented and error bars represent SEM. Statistical analyses were performed using a one-way ANOVA followed by a Dunnett’s multiple comparison
test versus unstimulated cells; ***p,0.001, **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0084246.g003
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To our knowledge this is one of only a few reports on the
definition of minimal length antigenic peptides recognised by
porcine CD8 T cells. A recent study used the NetMHCpan
prediction algorithm [28] to identify a 9mer peptide (MTA-
HITVPY) from the P1 capsid antigen of the foot-and-mouth
disease virus (FMDV) that bound the SLA allele SLA-1*0401
[29,30]. It was subsequently shown that a SLA-1*0401/MTA-
HITVPY tetramer stained CD8 T cells from SLA matched
FMDV vaccinated pigs and the size of the stained population
correlated with cytotoxic responses in these animals [30]. In
support of this immunoinformatics approach, the CSFV poly-
protein was screened for binding to potential restricting alleles
(based on the SLA class I Lr typing results) and two of the peptides
NS21223–1230 and NS31902–1912 were predicted by NetMHCpan
(www.cbs.dtu.dk/services/NetMHCpan/) to bind strongly to at
least one of the class I alleles potentially present in each of the
restricting haplotypes: SLA-2*12.01 for NS21223–1230 (potentially
present in both haplotypes Lr-38.0 and Lr-22.0) and NS31902–1912
was predicted to strongly bind SLA-1*08.01 (Lr-07-0), SLA-
3*07.01 (Lr-28.0);and SLA-2*01.01 and SLA-2*01.02 (Lr-01.0)
(data not shown).
Immunodominance in CD8 T cell responses is thought to arise
primarily as a consequence of the limitations of peptides to bind
with high-affinity to available MHC class I molecules, with
additional limitations in antigen processing and the CD8 T cell
receptor repertoire also playing a role. Only approximately 1/
2000 of the peptides within an antigen can achieve immunodo-
minant status with a given MHC class I allele [31]. Immunodo-
minance is thought to be critical for immunity since numerically
prominent CD8 T cells have been shown to confer more effective
protection than T cells specific for subdominant epitopes. It has
also been shown that the efficacy of peptides in providing
protection against a viral challenge is proportional to their binding
affinity for the restricting MHC class I molecule [32]. In HIV-1
infection it has been shown that immunodominant CD8 T cell
responses may limit virus replication and they are the primary
targets of escape mutations [33,34]. Immunodominance of CD8 T
cell responses to Flaviviruses has also been described, with
disparity in the degree depending on the virus/host system studied
[35,36]. A recent study, utilising a similar strategy to the present
one, assessed the specificity of human T cell response to Dengue
virus. Using a cohort of 25 patients, 21 novel CD8 T cell epitopes
were identified, with NS3 and NS5 being the most antigenic and
the majority of epitopes being recognised by single patients [35].
Immunodominance may also be a key factor in determining the
strain specificity of immunity if directed against polymorphic
Figure 4. Identification of minimal length antigenic peptides recognised by CSFV specific CD8 T cells. PBMC from pigs AN5, AN7, AN11
and AN13, collected at day 28 or cryopreserved at later time-points were stimulated with the identified 15mer or consensus 11mer antigenic peptides
and the truncated derivatives of NS5A LSRVDNALLKF, NS2 LISTVTGIFLI and E2 RYYEPRDSYFQ and IFN-c expression by CD8 T cells assessed by flow
cytometry. Panels A, B and C shows the mean unstimulated corrected % IFN-c expressing CD8 T cells +/2 SEM. Statistical analyses were performed
using a one-way ANOVA followed by a Dunnett’s multiple comparison test versus the previously identified 11mer antigenic peptide; ***p,0.001,
**p,0.01, *p,0.05. Panels D-H show reactivity against a log10 dilution series of the identified minimal length antigenic peptides (NS5A RVDNALLKF,
NS2 STVTGIFL and E2 YEPRDSYF) or antigenic regions (core PESRKKLEKALLAWA and NS3 VEYSFIFLDEY).
doi:10.1371/journal.pone.0084246.g004
Table 2. Conservation of identified CD8 T cell epitopes/antigenic regions among different CSFV isolates and the related
pestiviruses, bovine viral diarrhoea virus (BVDV) and border disease virus (BDV).
Virus Strain Genotype GenBank core241–255 NS31902–1912 E2996–1003 NS21223–1230 NS5A3070–3078
CSFV C-strain Riems 1.1 AY259122.1 PESRKKLEKALLAWA VEYSFIFLDEY YEPRDSYF STVTGIFL RVDNALLKF
CSFV Brescia 1.1 AF091661 ............... ........... ........ ........ .........
CSFV Alfort/187 1.1 X87939.1 ............... ........... ........ ........ .........
CSFV KC Vaccine 1.1 AF099102 ............... ........... ........ ........ .........
CSFV ALD 1.1 D49532 ............... ........... ........ ........ .........
CSFV GPE2 1.1 D49533 ............... ........... ........ ........ .........
CSFV Alfort-A19 1.1 U90951 ............... ........... ........ ........ .........
CSFV cF114 1.1 AF333000 ............... ........... ........ ........ .........
CSFV Shimen 1.1 AF092448 ............... ........... ........ ........ K........
CSFV Koslov 1.1 HM237795 ............... ........... ........ ........ .........
CSFV SWH 1.1 DQ127910 ............... ........... ........ ........ .........
CSFV Penevezys 2.1 HQ148063 ............... ....Y...... ........ .......M ...T.....
CSFV UK2000/7.1 2.1 * ............... ....Y...... ........ ........ K..T.....
CSFV Borken 2.3 GU233731 ............... ........... ........ ........ ...T.....
CSFV Alfort Tu¨bingen 2.3 AA43844 ............... ........... ........ ........ ...T.....
CSFV CBR/93 3.3 # L.............. ........... ........ ........ K..DT....
CSFV 94.4/IL/94/TWN 3.4 AY646427 ............... ........... ........ ........ K..K.....
BVDV NADL 1a AJ133738 Q.............. ....Y...... F....... .L.S.V.. D..PE.SEM
BDV BD31 1a U70263 ............... ....Y...... .....N.. .I.S.... D.EQD..EY
*CSFV UK2000/7.1: core and E2 (JQ411582), NS2 (KF771869), NS3 (KF771871) and NS5A (KF771873).
#CSFV CBR/93: core (KF784898), E2 (KF771867), NS2 (KF771868), NS3 (KF771870) and NS5A (KF771872).
doi:10.1371/journal.pone.0084246.t002
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epitopes. The identified epitopes in this study were well conserved
amongst CSFV isolates, although for most of these variants it
remains to be determined whether these substitutions could affect
T cell recognition. NetMHCpan predicted that the mutation of
tyrosine in place of a phenylalanine at position 1906 of the NS3
11mer VEYSFIFLDEY would not affect the binding to SLA class
I alleles and we were able to show this mutation did not affect T
cell reactivity. Moreover, the antigenic core241–255 peptide and the
E2996–1003 and NS31902–1912 epitopes are well conserved between
CSFV, BVDV and BDV. Such conserved T cell epitopes could
enhance the efficacy of a BVDV/CSFV chimeric vaccine. It has
recently been reported that the chimeric vaccine CP7_E2alf
induces rapid protection, comparable to the C-strain vaccine
[12,37]. Since this protection precedes the appearance of
neutralizing antibodies, it may be that T cell responses against
epitopes conserved between BVDV and CSFV are contributing to
the protective effect. Support for this hypothesis also stems from
our recent studies that showed a close temporal correlation
between the induction of CSFV-specific T cell IFN-c responses
and rapid protection induced by the C-strain vaccine [5] and that
T cells from these animals cross-react with BVDV derived
peptides [6].
Several studies have identified E2 and NS3 as targets of the T
cell response against CSFV [6–10]. However, our results provide
strong evidence that at least in the context of responses induced by
C-strain CSFV, E2 and NS3 are not necessarily the major T cell
antigens, and other CSFV proteins may be important targets of
the CD8 T cell response. These results however may not limit the
design of a marker vaccine based on only one or two
immunodominant antigens. A study on the related yellow fever
virus showed that, in case of abrogation of the dominant CD8 T
cell epitope, the frequencies of T cells recognizing the subdom-
inant CD8 T cell epitope increased dramatically [36]. A previous
study showed that vaccination with a IFN-a adjuvanted subunit
CSFV E2 vaccine fully protected pigs against a challenge
administered only 7 days later, suggesting that a T cell response
directed solely against E2 may be protective [38]. A recent
evaluation of dendrimeric peptide formulations of linear B cell
epitopes from E2 and a CD8 T cell antigenic peptide from NS3
induced the production of both neutralizing antibodies and IFN-c
producing cells, which resulted in a degree of protection against
CSFV [39]. Significantly, the protection achieved was greatest
when the T cell antigenic peptide was included together with the B
cell epitopes [40]. Incorporation of T cell epitopes identified in the
present study might further enhance the development of such a
marker vaccine approach.
We observed that all the identified peptides were able to induce
CD107a mobilization in IFN-c+ CD8 T cells. Translocation of
lysosomal-associated membrane protein 1 (LAMP1/CD107a) to
the cell membrane has been validated as a marker of cytotoxic
degranulation by CD8 T and NK cells [41]. Our data support
previous studies, which report the ability of the viral antigens E2
Figure 5. Recognition of the identified epitopes by CD8 T cells from C-strain vaccinated pigs challenged with divergent CSFV
strains. PBMC from pigs vaccinated with C-strain CSFV and challenged with CSFV isolate UK2000/7.1 (A) or CBR/93 (B), collected 9 or 12 days post-
challenge, were stimulated with antigenic peptides NS2 STVTGIFL and NS3 VEYSFIFLDEY. IFN-c expression by CD8 T cells assessed by flow cytometry
and graphs show the mean unstimulated-corrected % IFN-c expressing CD8 T cells +/2 SEM. Statistical analyses were performed using a one-way
ANOVA followed by a Dunnett’s multiple comparison test versus the un-stimulated control; **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0084246.g005
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and NS3 to elicit cytotoxic activity in vaccinated pigs [7–10] and
suggest that these T cells possessed cytotoxic activity in addition to
cytokine release. We also assessed the polyfunctionality of the
peptide-specific CD8 T cell populations, by assessing co-expres-
sion of IFN-c, TNF-a and IL-2, since this may be central to their
protective capacity. Studies on HCV have shown that vaccination
with vectors expressing NS3 and NS4a proteins induce specific
polyfunctional CD8 T cells which are associated with protection
Table 3. SLA class I low-resolution (Lr) haplotypes of C-strain vaccinated pigs and CD8 T cell reactivity against identified antigenic
peptides.
Pig n6# SLA class I haplotype SLA allele specificity
,
Antigenic peptide
SLA-1 SLA-2 SLA-3
AN5 Lr-04.0 04XX 04XX 04XX/hb06 NS5A3070–3078
Lr-24.0 blank 06XX 04XX/hb06
AN7 Lr-16.0 mod* 11XX w09XX 06XX NS21223–1230
Lr-38.0 15XX 12XX 04XX/hb06
AN11 Lr-07.0 08XX 05XX 07XX NS31902–1912 E2996–1003
Lr-28.0 09XX+15XX 05XX 07XX
AN13 Lr-32.0 07XX 02XX 04XX/hb06 core241–255
Lr-37.0 07XX w09XX 05XX
AD53 Lr-22.0 08XX 12XX 06XX(0601) NS21223–1230
Lr-37.0 07XX w09XX 05XX
AD56 Lr-22.0 08XX 12XX 06XX(0601) NS21223–1230
Lr-37.0 07XX w09XX 05XX
AD62 Lr-22.0 08XX 12XX 06XX(0601) NS21223–1230
Lr-55.0 15XX es22 04XX/hb06
AD65 Lr-22.0 08XX 12XX 06XX(0601) NS21223–1230
Lr-22.0 08XX 12XX 06XX(0601)
AD57 Lr-01.0 01XX 01XX 01XX NS31902–1912
Lr-37.0 07XX w09XX 05XX
AD64 Lr-01.0 01XX 01XX 01XX NS31902–1912
Lr-22.0 08XX 12XX 06XX(0601)
AD66 Lr-01.0 01XX 01XX 01XX NS31902–1912
Lr-22.0 08XX 12XX 06XX(0601)
AD52 Lr-31.0/63.0 15XX 16XX 07XX
Lr-36.0 02XX+15XX 11XX 01XX
AD55 Lr-36.0 02XX+15XX 11XX 01XX
Lr-45.0 08XX+cs02 w08XX+10XX 07XX
AE15 Lr-22.0 08XX 12XX 06XX(0601) NS21223–1230
Lr-37.0 07XX w09XX 05XX
AE17 Lr-22.0 08XX 12XX 06XX(0601) NS21223–1230
Lr-37.0 07XX w09XX 05XX
AE04 Lr-01.0 01XX 01XX 01XX NS31902–1912
Lr-22.0 08XX 12XX 06XX(0601)
AE08 Lr-01.0 01XX 01XX 01XX NS31902–1912
Lr-01.0 01XX 01XX 01XX
AE16 Lr-01.0 01XX 01XX 01XX NS31902–1912
Lr-55.0 15XX es22 04XX/hb06
AE03 Lr-53.0 blank es22/15XX 08XX
Lr-55.0 15XX es22 04XX/hb06
AE05 Lr-31.0/63.0 15XX 16XX 07XX
Lr-31.0/63.0 15XX 16XX 07XX
#C-strain vaccinated pigs were challenged with CSFV Brescia (AN), UK2000/7.1 (AD) and CBR/93 (AE).
,Medium-/high-resolution specificity not determined.
*16.0 mod.: SLA-1*11XX instead of SLA-1*04XX.
doi:10.1371/journal.pone.0084246.t003
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[14,15]. However, the majority of peptide-specific CD8 T cells
expressed IFN-c alone or IFN-c and TNF-a with only a small
percentage co-expressing IFN-c TNF-a and IL-2. Interestingly, as
observed in other systems [42,43], the subset expressing all three
cytokines showed the highest ‘quality’ of response producing more
IFN-c on a per cell basis.
Analysis of activation markers showed that the majority of the
CD8 T cells releasing IFN-c after peptide stimulation did not
express the alpha chain of the IL-2 receptor (CD25). In contrast, a
previous study reported variable expression of this marker on
CSFV-specific IFN-c CD8 T cells [44]. We speculate that the
absence of CD25 expression is not indicative of a naive state of
CD8 T cells, but could reflect a memory phenotype of these cells
since a previous study reports that after antigen stimulation some
human CD8 T cells express high levels of CD25, whereas others
display low levels of this marker and the latter preferentially
differentiate into long-lived functional memory cells [45]. Similar
to what has been described for human CD8 T cell responses to
other Flaviviruses, variable levels of expression of CD27 were
observed on peptide-specific CD8 T cells [15,46]. Based on data
from human CD8 T cells this may indicate that the majority of
CSFV epitope-specific CD8 T cell populations may be T effector
memory (TEM) cells [47]. Our results suggest that vaccine
strategies should be adopted in order to drive the generation of
peptide-specific cytotoxic CD8 TEM cells. A peptide-based vaccine
targeting dendritic cells to provide a strong signal to naive CD8 T
Figure 6. Phenotypic characterization of CSFV epitope-specific CD8 T cells. Cryopreserved PBMC from pigs AN5, AN7, AN11 and AN13 were
stimulated with the identified antigenic peptides and the phenotype of IFN-c expressing CD8 T cells determined by flow cytometry. Dot plots shows
representative data of the expression of IFN-c versus CD107a, CD25 and CD27 by singlet, live CD8 T cells cultures in the presence or absence of CSFV
antigenic peptides. The table reports the mean unstimulated-corrected % expression of these markers by peptide-specific IFN-c+ CD8 T cells from
triplicate cultures +/2 SEM.
doi:10.1371/journal.pone.0084246.g006
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cells should be designed, with the inclusion of cytokines (IL-12 and
IFN-c) or pathogen-recognition receptor agonists as adjuvants.
By utilising a comprehensive approach to determine the antigen
specificity of the CD8 T cell response, we have provided strong
evidence for immunodominance in the T cell response to CSFV.
CD8 T cell responses of individual animals were uniquely focussed
on only one or two epitopes which were mapped on the core, E2
and non-structural proteins NS2, NS3 and NS5A. The individual
responses were associated with the expression of distinct MHC
class I haplotypes and for two of the peptides there was evidence
that they are presented by alleles present in other haplotypes. The
five identified antigenic peptides were highly conserved across
CSFV isolates, and for some were also well conserved when
aligned against the other pestiviruses. The responding CD8 T cells
displayed cytotoxicity, with the majority of IFN-c+ cells co-
expressing the marker CD107a, and populations also releasing
TNF-a and/or IL-2. The antigens and epitopes identified and
characterised in this study therefore represent attractive vaccine
candidates that may be evaluated in the quest to develop the next
generation of CSFV vaccines.
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